Status:
UNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy
Lead Sponsor:
Wolfson Medical Center
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Since the pathophysiology of BIPN still remains unclear, in the present study we are going to assess the development of BIPN in newly diagnosed myeloma patients, based on clinical neurological examina...
Detailed Description
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination with other novel agents for the treatment of multiple myeloma (MM). Peripheral neuropathy is a sign...
Eligibility Criteria
Inclusion
- A total of 30 newly diagnosed patients (age \> 18 years) with multiple myeloma (stage3 Durie and Salmon, ECOG-performance status \<2), who are candidates for bortezomib therapy will be enrolled in the study (duration of the study 6 months).
Exclusion
- Patients with relapsed or progressive multiple myeloma.
- Performance status \> 2.
- Prior treatment with neuropathic agents such as Oncovin and thalidomide.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01171443
Start Date
August 1 2010
End Date
August 1 2011
Last Update
July 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wolfsson Medical Center
Holon, Israel, Israel